Adipokine RBP4 Drives Ovarian Cancer Cell Migration

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2018 Apr 13

PMID 29642915

Citations 33

Authors

Yanyan Wang

Yilin Wang

Zhenyu Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Obesity has been linked to several types of cancers including ovarian cancer. Retinol binding protein 4 (RBP4) is an adipokine that drives the development of hyperinsulinemia and type II diabetes in obesity patients and animals. Previously, we have identified RBP4 as a serum marker for ovarian cancer. Here we further explored the consequence of RBP4 upregulation in ovarian cancer cells and its molecular mechanism.

Results: Our results show that RBP4 is overexpressed in ovarian cancer cells to the same extent as in adipose tissues. The overexpression of RBP4 in ovarian cancer cells promotes cancer cell migration and proliferation. At molecular level, cancer progression factors MMP2 and MMP9 are induced in response to RBP4 overexpression. We further investigated which signaling pathways are utilized by RBP4 to activate ovarian cancer cell migration. We found RhoA/Rock1 pathway is turned on and CyclinD1 is upregulated in RBP4 overexpressed cells. Inhibition of RhoA/Rock1 pathway reduces the RBP4-induced MMP2 and MMP9 expression. The RBP4 action is depend on its associated ligand vitamin A/retinol acid (RA) and possibly involves similar pathways as for conferring insulin resistance. Moreover, we show that knockdown of RBP4 significantly reduce cancer cell migration and proliferation as well as expressions of oncogenic factors.

Conclusions: Our results indicated that RBP4 can drive ovarian cancer cell migration and proliferation via RhoA/Rock1 and ERK pathway. It suggests that RBP4 act as a oncogene in ovarian cancer cells. Thus, RBP4 could be a molecular bridge between obesity and cancers and a potential target for treating obese cancer patients.

Citing Articles

Retinol-Binding Protein 4 as a Biomarker in Cancer: Insights from a Pan-Cancer Analysis of Expression, Immune Infiltration, and Methylation.

Zhao J, Liu Y, Zhou L, Liu Y Genes (Basel). 2025; 16(2).

PMID: 40004479 PMC: 11855459. DOI: 10.3390/genes16020150.

A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression.

Mohd Faizal N, Shai S, Savaliya B, Karen-Ng L, Kumari R, Kumar R Biomedicines. 2025; 13(1).

PMID: 39857718 PMC: 11759772. DOI: 10.3390/biomedicines13010134.

The role of novel adipokines in hepatocellular carcinoma progression: a mini review.

Hu P, Guo D, Cao K, Xu T Am J Cancer Res. 2024; 14(11):5471-5485.

PMID: 39659942 PMC: 11626281. DOI: 10.62347/PZDM1736.

Elevated RBP4 in Subclinical Ketosis Cows Inhibits Follicular Granulosa Cell Proliferation and Steroid Hormone Synthesis.

Zhao C, Xu R, Yan W, Jiang B, Feng S, Wang X Animals (Basel). 2024; 14(21).

PMID: 39518840 PMC: 11545013. DOI: 10.3390/ani14213118.

Inhibition of STRA6 suppresses NSCLC growth via blocking STAT3/SREBP-1c axis-mediated lipogenesis.

Zhou Y, Zhou R, Wang N, Zhao T, Qiu P, Gao C Mol Cell Biochem. 2024; 480(3):1715-1730.

PMID: 39168951 DOI: 10.1007/s11010-024-05085-y.

References

Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E . Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res. 2008; 38(8):810-7. DOI: 10.1111/j.1872-034X.2008.00333.x. View

Morikawa K, Hanada H, Hirota K, Nonaka M, Ikeda C . All-trans retinoic acid displays multiple effects on the growth, lipogenesis and adipokine gene expression of AML-I preadipocyte cell line. Cell Biol Int. 2013; 37(1):36-46. DOI: 10.1002/cbin.10005. View

Graham T, Yang Q, Bluher M, Hammarstedt A, Ciaraldi T, Henry R . Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006; 354(24):2552-63. DOI: 10.1056/NEJMoa054862. View

Terra R, Wang X, Hu Y, Charpentier T, Lamarre A, Zhong M . To investigate the necessity of STRA6 upregulation in T cells during T cell immune responses. PLoS One. 2014; 8(12):e82808. PMC: 3876989. DOI: 10.1371/journal.pone.0082808. View

Selvaggi . Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Arch Pathol Lab Med. 2000; 124(3):477. View

Noy N, Li L, Abola M, Berger N . Is retinol binding protein 4 a link between adiposity and cancer?. Horm Mol Biol Clin Investig. 2015; 23(2):39-46. PMC: 4625546. DOI: 10.1515/hmbci-2015-0019. View

Liu Y, Metzinger M, Lewellen K, Cripps S, Carey K, Harper E . Obesity Contributes to Ovarian Cancer Metastatic Success through Increased Lipogenesis, Enhanced Vascularity, and Decreased Infiltration of M1 Macrophages. Cancer Res. 2015; 75(23):5046-57. PMC: 4668203. DOI: 10.1158/0008-5472.CAN-15-0706. View

Norseen J, Hosooka T, Hammarstedt A, Yore M, Kant S, Aryal P . Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol. 2012; 32(10):2010-9. PMC: 3347417. DOI: 10.1128/MCB.06193-11. View

Berry D, Croniger C, Ghyselinck N, Noy N . Transthyretin blocks retinol uptake and cell signaling by the holo-retinol-binding protein receptor STRA6. Mol Cell Biol. 2012; 32(19):3851-9. PMC: 3457529. DOI: 10.1128/MCB.00775-12. View

10.

Bai H, Li H, Li W, Gui T, Yang J, Cao D . The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget. 2015; 6(28):25520-32. PMC: 4694849. DOI: 10.18632/oncotarget.4550. View

11.

Jiao C, Cui L, Ma A, Li N, Si H . Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study. PLoS One. 2016; 11(12):e0167498. PMC: 5176270. DOI: 10.1371/journal.pone.0167498. View

12.

Gavi S, Stuart L, Kelly P, Melendez M, Mynarcik D, Gelato M . Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab. 2007; 92(5):1886-90. DOI: 10.1210/jc.2006-1815. View

13.

Fedders R, Muenzner M, Schupp M . Retinol binding protein 4 and its membrane receptors: a metabolic perspective. Horm Mol Biol Clin Investig. 2015; 22(1):27-37. DOI: 10.1515/hmbci-2015-0013. View

14.

Cheng Y, Liu C, Zhang N, Wang S, Zhang Z . Proteomics analysis for finding serum markers of ovarian cancer. Biomed Res Int. 2014; 2014:179040. PMC: 4164372. DOI: 10.1155/2014/179040. View

15.

Uehara H, Takahashi T, Izumi K . Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin. Int J Oncol. 2013; 43(2):365-74. PMC: 3775580. DOI: 10.3892/ijo.2013.1954. View

16.

Blaner W . Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev. 1989; 10(3):308-16. DOI: 10.1210/edrv-10-3-308. View

17.

Narumiya S, Tanji M, Ishizaki T . Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009; 28(1-2):65-76. DOI: 10.1007/s10555-008-9170-7. View

18.

Berry D, Jin H, Majumdar A, Noy N . Signaling by vitamin A and retinol-binding protein regulates gene expression to inhibit insulin responses. Proc Natl Acad Sci U S A. 2011; 108(11):4340-5. PMC: 3060239. DOI: 10.1073/pnas.1011115108. View

19.

Chang H, Huang H, Kao Y, Chen S, Wu S, Hung T . The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells. Chem Biol Interact. 2009; 183(1):172-80. DOI: 10.1016/j.cbi.2009.10.018. View

20.

Wang D, Zhao Y, Wang L, Ren G, Wang F, Xia Z . Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection. J Cancer Res Clin Oncol. 2010; 137(4):651-8. DOI: 10.1007/s00432-010-0927-3. View